Iridex Stock Gains After Posting Highest Sales Since 2007

  • Iridex Corporation IRIX reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million.
  • Cyclo G6 product family generated sales of $3.6 million, +70% Y/Y on 16,000 probes sold, up 103% Y/Y.
  • Iridex sold 47 Cyclo G6 Glaucoma Laser Systems, compared to 42 a year ago.
  • Retina product revenue nearly tripled to $7.6 million, with 28% from PASCAL products acquired from Topcon.
  • Gross margin expanded from 38.7% to 45.5%, primarily attributable to the impact of production efficiency initiatives, greater overhead absorption, and increase in higher-margin probes.
  • The Company reported Q2 EPS of $0.09, a turnaround from EPS loss of $(0.20), ahead of Wall Street estimate of $(0.20).
  • Iridex ended Q2 with a cash balance of $26.3 million.
  • FY21 Guidance: Iridex forecasts FY21 revenue of $50 million - $52 million, +38% - 43% Y/Y. Earlier sales guidance was $48 million - $51 million. 
  • Cyclo G6 probe sales are expected to increase to 58,000 - 60,000 from prior guidance of 56,000 - 59,000. 
  • Glaucoma Laser System sales expectation remains unchanged at 250 - 275.
  • Price Action: IRIX shares are up 8.33% at $7.15 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefsglaucoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!